Overview
Title
To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
ELI5 AI
The bill says that a big boss in charge of health and medicine has to make new rules about how they test medicines without using people or animals, and they need to do it in six months. It also wants to fix a mistake where two parts of the same important book about medicines have the same name.
Summary AI
S. 5046 is a bill that requires the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, to issue a final rule regarding nonclinical testing methods. This bill, also known as the "FDA Modernization Act 3.0," mandates that the rule be published within 180 days of the bill's enactment. Additionally, it updates the Federal Food, Drug, and Cosmetic Act by renaming a subsection to prevent confusion due to duplicate labeling of subsections.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The bill titled "FDA Modernization Act 3.0," introduced in the 118th Congress, seeks to streamline regulatory processes concerning nonclinical testing methods. Its core mandate is for the Secretary of Health and Human Services, via the Commissioner of Food and Drugs, to publish a final rule to implement an existing section of the Federal Food, Drug, and Cosmetic Act. However, the bill addresses a specific need to adjust legal numeration within this Act to rectify existing legislative ambiguities.
Summary of Significant Issues
A critical aspect of the bill is the requirement for action within a strict 180-day timeline. This constraint could pose challenges by potentially leading to hurried rule formulation without enough public dialogue or comprehensive examination of the rule's potential effects. Furthermore, an issue emerges from the technical complexity related to a duplicate labeling occurrence in the legislative sections, which might create confusion and interpretation difficulties. Lastly, the absence of detailed definitions for essential terms like "nonclinical testing methods" contributes to the potential for diverse interpretations, which could result in inconsistent application or understanding among stakeholders.
Broad Public Impact
This bill could have a widespread impact on the development and approval processes for food and drug products across the United States. By focusing on nonclinical testing methods, there is an intention to modernize how testing and approvals are conducted, potentially speeding up processes and reducing animal testing. While these changes are intended to improve efficiency and reduce traditional testing burdens, stakeholders may have concerns about the adequacy of these methods in ensuring safety and efficacy.
Stakeholder Impacts
For regulators and federal agencies, this bill necessitates a prompt and possibly challenging adoption of new rules. The timeline might strain resources and curtail comprehensive stakeholder engagement. Companies involved in pharmaceuticals and biotechnology might stand to benefit from potentially accelerated product development cycles as a result of streamlined approvals. Conversely, some groups, notably health and safety advocates, could express apprehensions over the adequacy of protections within hastened timeframes and new testing methodologies.
Meanwhile, legal practitioners and policymakers will need to tread carefully to ensure clarity and precision in legislative language, especially regarding subsection numbering and terminology. This is vital to avoid legal disputes and enforcement discrepancies.
Overall, while the intent of the "FDA Modernization Act 3.0" is to update and refine regulatory processes, the execution will need careful balancing of speed with due diligence to protect public health and maintain industry standards.
Issues
Section 2: The requirement for the Secretary of Health and Human Services to publish a final rule within 180 days may lead to a rushed process, potentially limiting adequate public comment or thorough evaluation of the rule's impacts.
Section 2: The existence of two subsections labeled (z) within section 505 of the Federal Food, Drug, and Cosmetic Act poses a risk for legal ambiguity and confusion in the interpretation and implementation of the regulations.
Section 2: The lack of clear definitions for terms such as 'nonclinical testing methods' could result in differing interpretations among stakeholders, which might affect the rule's implementation and effectiveness.
Section 1: The short title 'FDA Modernization Act 3.0' lacks context or explanation, which could lead to confusion or misinterpretation about the scope and intent of the act.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the bill states that it can be referred to as the "FDA Modernization Act 3.0".
2. Regulations on nonclinical testing methods Read Opens in new tab
Summary AI
The Secretary of Health and Human Services is required to publish a rule on nonclinical testing methods within 180 days, as part of a larger law covering food and drugs. Additionally, there's a change in the legal numbering for parts of the law related to diverse clinical trials.